Search results for: A. Punt

Items from 1 to 20 out of 92 results

article

Time‐varying prognostic value of primary tumor sidedness in metastatic colorectal cancer: A population‐based study and meta‐analysis

Dave E. W. Kruijssen, Auke J. S. Kuil, Geraldine R. Vink, Cornelis J. A. Punt, more

International Journal of Cancer > 152 > 7 > 1360 - 1369

We studied the prognostic value of primary tumor sidedness in metastatic colorectal cancer over time and across treatment lines. Population data on synchronous metastatic colorectal cancer patients were extracted from the Netherlands Cancer Registry and SEER database. Pubmed, EMBASE and Cochrane library were searched for prospective studies on metastatic colorectal cancer to conduct a meta‐analysis...

article

Predictive value of chromosome 18q11.2‐q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III‐trial AGITG‐MAX

Erik Dijk, Erik Werkhoven, Rebecca Asher, Jennifer K. Mooi, more

International Journal of Cancer > 151 > 7 > 1166 - 1174

The VEGF‐A monoclonal antibody bevacizumab is currently recommended for first‐line treatment of all metastatic colorectal cancer (mCRC) patients. Cost‐benefit ratio and side‐effects however necessitate patient selection. A large retrospective yet nonrandomized study showed that patients with loss of chromosome 18q11.2‐q12.1 in the tumor and treated with bevacizumab have 3 months improved median progression‐free...

article

Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients: A prospective cohort study

Gabrielle Jongeneel, Marjolein J. E. Greuter, Felice N. Erning, Jos W. R. Twisk, more

International Journal of Cancer > 148 > 11 > 2702 - 2711

Patient's quality of life should be included in clinical decision making regarding the administration of adjuvant chemotherapy (ACT) in stage II/III colon cancer. Therefore, quality of life, summarized as health utility (HU), was evaluated for patients treated with and without ACT. Furthermore, the role of chemotherapy–induced peripheral neuropathy (CIPN) on HU was evaluated. Patients diagnosed with...

article

Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real‐life data

Patricia A. H. Hamers, Marloes A. G. Elferink, Rebecca K. Stellato, Cornelis J. A. Punt, more

International Journal of Cancer > 148 > 2 > 296 - 306

Reported median overall survival (mOS) in metastatic colorectal cancer (mCRC) patients participating in systemic therapy trials has increased to over 30 months. It is uncertain whether trial results translate to real‐life populations. Moreover, patients prefer presentation of multiple survival scenarios. Population‐based data of all stage IV CRC patients diagnosed between 2008 and 2016 were obtained...

article

Multicentre study of short‐course radiotherapy, systemic therapy and resection/ablation for stage IV rectal cancer

E. N. D. Kok, K. Havenga, P. J. Tanis, J. H. W. Wilt, more

British Journal of Surgery > 107 > 5 > 537 - 545

Background The optimal treatment sequence for patients with rectal cancer and synchronous liver metastases remains unclear. The aim of this study was to evaluate the feasibility and effectiveness of short‐course pelvic radiotherapy (5 × 5 Gy) followed by systemic therapy and local treatment of all tumour sites in patients with potentially curable stage IV rectal cancer in daily practice. Methods...

article

Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6)

Koen P. Rovers, Checca Bakkers, Geert A. A. M. Simkens, Jacobus W. A. Burger, more

BMC Cancer > 2019 > 19 > 1 > 1-15

Background Upfront cytoreductive surgery with HIPEC (CRS-HIPEC) is the standard treatment for isolated resectable colorectal peritoneal metastases (PM) in the Netherlands. This study investigates whether addition of perioperative systemic therapy to CRS-HIPEC improves oncological outcomes. Methods This open-label, parallel-group, phase II-III, randomised, superiority study is performed in nine Dutch...

article

Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the multicenter randomized controlled PUMP trial

F. E. Buisman, M. Y. V. Homs, D. J. Grünhagen, W. F. Filipe, more

BMC Cancer > 2019 > 19 > 1 > 1-9

Background Recurrences are reported in 70% of all patients after resection of colorectal liver metastases (CRLM), in which half are confined to the liver. Adjuvant hepatic arterial infusion pump (HAIP) chemotherapy aims to reduce the risk of intrahepatic recurrence. A large retrospective propensity score analysis demonstrated that HAIP chemotherapy is particularly effective in patients with low-risk...

article

Inventory of oncologists’ unmet needs for tools to support decision-making about palliative treatment for metastatic colorectal cancer

Ellen G. Engelhardt, Dóra Révész, Hans J. Tamminga, Cornelis J. A. Punt, more

BMC Medical Informatics and Decision Making > 2018 > 18 > 1 > 1-7

Background Decision-making about palliative care for metastatic colorectal cancer (mCRC) consists of many different treatment-related decisions, and there generally is no best treatment option. Decision support systems (DSS), e.g., prognostic calculators, can aid oncologists’ decision-making. DSS that contain features tailored to the needs of oncologists are more likely to be implemented in clinical...

article

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands

Carin A. Uyl-de Groot, Elisabeth M. van Rooijen, Cornelis J. A. Punt, Chris P. Pescott

Health Economics Review > 2018 > 8 > 1 > 1-8

Objective To assess the cost effectiveness of cetuximab in third-line treatment of patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) in routine clinical practice compared with best supportive care (BSC). Methods Patients (n = 287) with KRAS wt mCRC treated with cetuximab or BSC in eight hospitals in the Netherlands between 2009 and 2012 were included in our real-world study....

article

Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands

Johannes J. M. Kwakman, G. Vink, J. H. Vestjens, L. V. Beerepoot, more

International Journal of Clinical Oncology > 2018 > 23 > 3 > 482-489

Background The RECOURSE trial showed clinical efficacy for trifluridine/tipiracil for refractory metastatic colorectal cancer patients. We assessed the feasibility and effectiveness of trifluridine/tipiracil in daily clinical practice in The Netherlands. Methods Medical records of patients from 17 centers treated in the trifluridine/tipiracil compassionate use program were reviewed and checked for...

article

Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer

Eva Versteijne, Eelco Lens, Astrid van der Horst, Arjan Bel, more

Strahlentherapie und Onkologie > 2017 > 193 > 8 > 630-638

Background The Dutch Pancreatic Cancer Group initiated the national, multicentre, controlled PREOPANC trial, randomising between preoperative radiochemotherapy and direct explorative laparotomy for patients with (borderline) resectable pancreatic cancer. The aim of this dummy run is to evaluate compliance with the radiotherapy protocol of this trial, and the quality of delineation and radiation plans...

article

Ethnic differences in colon cancer care in the Netherlands: a nationwide registry-based study

M. Lamkaddem, M. A. G. Elferink, M. C. Seeleman, E. Dekker, more

BMC Cancer > 2017 > 17 > 1 > 1-8

Background Ethnic differences in colon cancer (CC) care were shown in the United States, but results are not directly applicable to European countries due to fundamental healthcare system differences. This is the first study addressing ethnic differences in treatment and survival for CC in the Netherlands. Methods Data of 101,882 patients diagnosed with CC in 1996–2011 were selected from the Netherlands...

article

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

Jan Franko, Qian Shi, Jeffrey P Meyers, Timothy S Maughan, more

The Lancet Oncology > 2016 > 17 > 12 > 1709-1719

Patients with peritoneal metastatic colorectal cancer have reduced overall survival compared with patients with metastatic colorectal cancer without peritoneal involvement. Here we further investigated the effect of the number and location of metastases in patients receiving first-line systemic chemotherapy. We analysed individual patient data for previously untreated patients enrolled in 14 phase...

article

Comparison of symptom clusters associated with fatigue in older and younger survivors of colorectal cancer

S. C. Agasi-Idenburg, M. S. Y. Thong, C. J. A. Punt, M. M. Stuiver, more

Supportive Care in Cancer > 2017 > 25 > 2 > 625-632

Purpose Cancer-related fatigue (CRF) is one of the most frequently reported symptoms in cancer survivors. To be able to optimally treat CRF, knowledge of symptoms that interact with CRF is helpful. During aging, changes occur in body composition with progressive deterioration in physiological functions and metabolic processes causing a decline of adaptive capacity. Therefore, symptoms caused by cancer...

article

Dose-dependent DNA adduct formation by cinnamaldehyde and other food-borne α,β-unsaturated aldehydes predicted by physiologically based in silico modelling

R. Kiwamoto, D. Ploeg, I.M.C.M. Rietjens, A. Punt

Toxicology in Vitro > 2016 > 31 > C > 114-125

Genotoxicity of α,β-unsaturated aldehydes shown in vitro raises a concern for the use of the aldehydes as food flavourings, while at low dose exposures the formation of DNA adducts may be prevented by detoxification. Unlike many α,β-unsaturated aldehydes for which in vivo data are absent, cinnamaldehyde was shown to be not genotoxic or carcinogenic in vivo. The present study aimed at comparing dose-dependent...

article

Evaluation of an oral uracil loading test to identify DPD‐deficient patients using a limited sampling strategy

Maurice C. Staveren, Andre B. P. Kuilenburg, Henk‐Jan Guchelaar, Judith Meijer, more

British Journal of Clinical Pharmacology > 81 > 3 > 553 - 561

AIMDihydropyrimidine dehydrogenase (DPD) deficiency can lead to severe toxicity following 5‐fluorouracil (5FU) or capecitabine (CAP) treatment. Uracil (U) can be used as a probe to determine systemic DPD activity. The present study was performed to assess the sensitivity and specificity of a U loading dose for detecting DPD deficiency. MethodsCancer patients with Common Toxicity Score (CTC) grade...

article

RE: Effects of adjuvant chemotherapy on recurrence, survival and quality of life in stage II colon cancer patients: a 24-month follow-up

F. N. van Erning, P. A. J. Vissers, C. J. A. Punt, V. E. P. P. Lemmens

Supportive Care in Cancer > 2016 > 24 > 10 > 4079-4080

article

Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity

Kalijn F. Bol, Erik H. J. G. Aarntzen, Jeanette M. Pots, Michel A. M. Olde Nordkamp, more

Cancer Immunology, Immunotherapy > 2016 > 65 > 3 > 327-339

Dendritic cell (DC)-based immunotherapy is explored worldwide in cancer patients, predominantly with DC matured with pro-inflammatory cytokines and prostaglandin E₂. We studied the safety and efficacy of vaccination with monocyte-derived DC matured with a cocktail of prophylactic vaccines that contain clinical-grade Toll-like receptor ligands (BCG, Typhim, Act-HIB) and prostaglandin E₂ (VAC-DC). Stage...

article

Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial

Eva Versteijne, Casper H. J. van Eijck, Cornelis J. A. Punt, Mustafa Suker, more

Trials > 2016 > 17 > 1 > 1-8

Background Pancreatic cancer is the fourth largest cause of cancer death in the United States and Europe with over 100,000 deaths per year in Europe alone. The overall 5-year survival ranges from 2–7 % and has hardly improved over the last two decades. Approximately 15 % of all patients have resectable disease at diagnosis, and of those, only a subgroup has a resectable tumour at surgical exploration...

article

A multi-centred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer

W. A. A. Borstlap, P. J. Tanis, T. W. A. Koedam, C. A. M. Marijnen, more

BMC Cancer > 2016 > 16 > 1 > 1-8

Background Rectal cancer surgery is accompanied with high morbidity and poor long term functional outcome. Screening programs have shown a shift towards more early staged cancers. Patients with early rectal cancer can potentially benefit significantly from rectal preserving therapy. For the earliest stage cancers, local excision is sufficient when the risk of lymph node disease and subsequent recurrence...

Publication date

Last 3 years (2)

Close

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

From:

To:
Set your own date range

Publication type

article (91)
book (1)

Keywords

METASTATIC COLORECTAL CANCER (8)
BEVACIZUMAB (7)
COLORECTAL CANCER (7)
DENDRITIC CELLS (6)
MELANOMA (5)
ADJUVANT CHEMOTHERAPY (4)
HYPOXIA (4)
IMMUNOTHERAPY (4)
COLON CANCER (3)
DNA ADDUCTS (3)
MATURATION (3)
CANCER (2)
CETUXIMAB (2)
FUNCTIONAL IMAGING (2)
HISTOPATHOLOGY (2)
LIVER METASTASES (2)
OVERALL SURVIVAL (2)
PHARMACOKINETICS (2)
PROGNOSTIC FACTOR (2)
RANDOMIZED CONTROLLED TRIAL (2)
RECTAL CANCER (2)
REPRODUCIBILITY (2)
RESPONSE MONITORING (2)
TCR (2)
THYMOCYTES (2)
TOLL-LIKE RECEPTOR LIGANDS (2)
Α,Β-UNSATURATED ALDEHYDES (2)
18F-FDG PET (1)
TRANS-2-HEXENAL (1)
(BORDERLINE) RESECTABLE PANCREATIC CANCER (1)
5‐FLUOROURACIL (1)
ADJUVANT (1)
ADJUVANT CHEMORADIOTHERAPY (1)
ADJUVANT HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) (1)
ADJUVANT PEGYLATED INTERFERON ALPHA-2B (1)
ADJUVANT THERAPY (1)
ADVANCED DISEASE (1)
AGE (1)
AH RECEPTOR (1)
ALTERED-PEPTIDE LIGANDS (1)
ANTIBODY (1)
ANTIGEN PRESENTATION (1)
ANTI‐VEGF MONOCLONAL ANTIBODY (1)
ASCITES (1)
BASIL (1)
BCL-2 (1)
BIM (1)
BIOENERGETICS (1)
CANCER IMMUNOTHERAPY (1)
CANCER RELATED FATIGUE (1)
CAPECITABINE (1)
CARBOGEN (1)
CEDIRANIB (1)
CELL TRAFFICKING (1)
CHEMORADIATION (1)
CHEMOTHERAPY (1)
CHROMOSOME 18Q (1)
CINNAMALDEHYDE (1)
CIRCULATING TUMOR CELLS (1)
CITRUS (1)
CLINICAL OUTCOME (1)
CLINICAL PROTOCOLS (1)
CLINICAL TRIAL (1)
COLON CARCINOMA (1)
COLORECTAL (1)
COLORECTAL LIVER METASTASIS (1)
COLORECTAL METASTASES (1)
COLORECTAL NEOPLASMS (1)
COMPASSIONATE USE (1)
COMPUTED TOMOGRAPHY (1)
COMPUTERTOMOGRAPHIE (1)
CONSEQUENCES OF DISTURBANCE (1)
COST EFFECTIVENESS (1)
CRUCIFEROUS (1)
CYCLOPROPYLPYRROLOINDOLE PRODRUG HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY PHARMACOKINETICS PLASMA CLEARANCE (1)
CYTOREDUCTION SURGICAL PROCEDURES (1)
DECISION SUPPORT TOOLS (1)
DENDRITIC CELL (1)
DIFFUSION WEIGHTED MAGNETIC RESONANCE IMAGING (1)
DIHYDROPYRIMIDINE DEHYDROGENASE (1)
DIVE MODELLING (1)
DNA REPAIR (1)
DOUBLE STRAND BREAK (DSB) (1)
E7070 (1)
ECOLOGY OF FEAR (1)
EORTC (1)
EPITHELIAL-MESENCHYMAL TRANSITION (1)
ESTRAGOLE (1)
ETHNIC MINORITIES (1)
EXPLORATIVE LAPAROTOMY (1)
FDG PET (1)
FEASIBILITY (1)
FIDUCIAL MARKERS (1)
FIDUCIAL-MARKER (1)
GASTROINTESTINAL ULCER (1)
GENOTOXICITY (1)
HEALTH CARE UTILISATION (1)
HEMATOLOGICAL TOXICITY (1)
HEPATIC ARTERIAL INFUSION (1)
HEPATIC RESECTION (1)
more

Data set

Springer (51)
Elsevier (27)
Wiley (12)
ACS (1)
ieee (1)

Journal

Cancer Immunology, Immunotherapy (9)
Annals of Oncology (7)
BMC Cancer (5)
Immunity (5)
Toxicology Letters (5)
International Journal of Cancer (4)
Investigational New Drugs (4)
Annals of Surgical Oncology (3)
British Journal of Surgery (3)
Toxicology and Applied Pharmacology (3)
Current Colorectal Cancer Reports (2)
Supportive Care in Cancer (2)
Targeted Oncology (2)
The Lancet (2)
The Lancet Oncology (2)
Toxicology in Vitro (2)
Trends in Immunology (2)
American Journal of Clinical Dermatology (1)
Applied Magnetic Resonance (1)
Archives of Toxicology (1)
BMC Medical Informatics and Decision Making (1)
British Journal of Clinical Pharmacology (1)
Cancer Chemotherapy and Pharmacology (1)
Cell (1)
Cellular and Molecular Life Sciences (1)
Chemical Research in Toxicology (1)
Chemico-Biological Interactions (1)
Contrast Media & Molecular Imaging (1)
Current Opinion in Immunology (1)
Diseases of the Colon & Rectum (1)
European Journal of Nuclear Medicine and Molecular Imaging (1)
European Radiology (1)
Health Economics Review (1)
Histopathology (1)
Immunology Today (1)
Indian Journal of Surgical Oncology (1)
International Journal of Clinical Oncology (1)
International Journal of Radiation Oncology, Biology, Physics (1)
Journal of Applied Ecology (1)
Magnetic Resonance in Medicine (1)
PharmacoEconomics (1)
Strahlentherapie und Onkologie (1)
Toxicology (1)
Trials (1)
Virchows Archiv (1)
memo - Magazine of European Medical Oncology (1)
more

INFONA - science communication portal

Search results for: A. Punt

Time‐varying prognostic value of primary tumor sidedness in metastatic colorectal cancer: A population‐based study and meta‐analysis

Predictive value of chromosome 18q11.2‐q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III‐trial AGITG‐MAX

Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients: A prospective cohort study

Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real‐life data

Multicentre study of short‐course radiotherapy, systemic therapy and resection/ablation for stage IV rectal cancer

Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6)

Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the multicenter randomized controlled PUMP trial

Inventory of oncologists’ unmet needs for tools to support decision-making about palliative treatment for metastatic colorectal cancer

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands

Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands

Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer

Ethnic differences in colon cancer care in the Netherlands: a nationwide registry-based study

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

Comparison of symptom clusters associated with fatigue in older and younger survivors of colorectal cancer

Dose-dependent DNA adduct formation by cinnamaldehyde and other food-borne α,β-unsaturated aldehydes predicted by physiologically based in silico modelling

Evaluation of an oral uracil loading test to identify DPD‐deficient patients using a limited sampling strategy

RE: Effects of adjuvant chemotherapy on recurrence, survival and quality of life in stage II colon cancer patients: a 24-month follow-up

Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity

Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial

A multi-centred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer

Filter options

Publication date

Publication type

Keywords

Data set

Journal

INFONA - science communication portal

Search results for: A. Punt

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Publication type

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options